Takeda Pharmaceutical Co Ltd (TKPHF)
26.64
+0.62
(+2.38%)
USD |
OTCM |
May 15, 13:28
Takeda Pharmaceutical Enterprise Value: 69.71B for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 69.71B |
| May 13, 2024 | 70.98B |
| May 10, 2024 | 70.98B |
| May 09, 2024 | 70.98B |
| May 08, 2024 | 68.96B |
| May 07, 2024 | 70.64B |
| May 06, 2024 | 70.64B |
| May 03, 2024 | 70.64B |
| May 02, 2024 | 70.64B |
| May 01, 2024 | 70.64B |
| April 30, 2024 | 69.76B |
| April 29, 2024 | 69.76B |
| April 26, 2024 | 69.76B |
| April 25, 2024 | 68.17B |
| April 24, 2024 | 69.32B |
| April 23, 2024 | 69.32B |
| April 22, 2024 | 69.32B |
| April 19, 2024 | 69.32B |
| April 18, 2024 | 70.49B |
| April 17, 2024 | 70.49B |
| April 16, 2024 | 70.49B |
| April 15, 2024 | 70.49B |
| April 12, 2024 | 70.49B |
| April 11, 2024 | 70.49B |
| April 10, 2024 | 70.49B |
| Date | Value |
|---|---|
| April 09, 2024 | 71.33B |
| April 08, 2024 | 70.60B |
| April 05, 2024 | 71.64B |
| April 04, 2024 | 70.34B |
| April 03, 2024 | 70.78B |
| April 02, 2024 | 70.78B |
| April 01, 2024 | 72.68B |
| March 31, 2024 | 73.52B |
| March 28, 2024 | 75.46B |
| March 27, 2024 | 75.46B |
| March 26, 2024 | 75.46B |
| March 25, 2024 | 75.46B |
| March 22, 2024 | 76.22B |
| March 21, 2024 | 76.22B |
| March 20, 2024 | 76.22B |
| March 19, 2024 | 76.22B |
| March 18, 2024 | 76.22B |
| March 15, 2024 | 76.22B |
| March 14, 2024 | 76.22B |
| March 13, 2024 | 76.99B |
| March 12, 2024 | 76.99B |
| March 11, 2024 | 77.38B |
| March 08, 2024 | 77.38B |
| March 07, 2024 | 75.54B |
| March 06, 2024 | 75.54B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
66.06B
Minimum
Oct 19 2022
106.88B
Maximum
Nov 19 2019
84.87B
Average
80.01B
Median
Apr 12 2023
Enterprise Value Benchmarks
| Nxera Pharma Co Ltd | 1.016B |
| PeptiDream Inc | 1.801B |
| Healios KK | 63.48M |
| AnGes Inc | 59.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.33M |
| Revenue (Quarterly) | 7.081B |
| Total Expenses (Quarterly) | 7.148B |
| EPS Diluted (Quarterly) | -0.0135 |
| Gross Profit Margin (Quarterly) | 63.60% |
| Profit Margin (Quarterly) | -0.29% |
| Earnings Yield | 2.41% |
| Operating Earnings Yield | 3.01% |
| Normalized Earnings Yield | 2.415 |